Motion sickness may have a hormone problem, and a new animal study names a specific culprit. Researchers reporting in PLoS One ↗ on September 25, 2026 found that atrial natriuretic peptide, a hormone the heart releases to shed salt and water, blocked motion-sickness responses in guinea pigs and mice by counteracting a second hormone, aldosterone, inside the inner ear.
The inner ear keeps the body balanced using a fluid called endolymph, and its volume has to stay under tight control. The study's chain of evidence runs like this. Spinning the animals, which is the standard way to provoke motion sickness in the lab, raised the level of aldosterone in their blood. Aldosterone is the body's main salt-retaining hormone, and holding onto salt pulls in water. When the researchers injected aldosterone directly, with no spinning at all, the animals developed the same motion-sickness-like signs. That points to the hormone itself, rather than the movement, as the proximate trigger.
Atrial natriuretic peptide does the reverse of aldosterone. It tells the kidney to dump salt and water and bring fluid volume down. In the treated animals, giving the peptide inhibited those aldosterone-driven responses. To show why, the team moved to cultured cells from the inner-ear lining and found that the peptide turned down the machinery aldosterone uses to move salt. It lowered the mineralocorticoid receptor, the docking protein aldosterone binds, and reduced that receptor's movement into the cell nucleus, where it switches genes on. It also cut two salt-transport proteins, the epithelial sodium channel and the sodium-potassium pump. Less of that machinery means less salt drawn into the endolymph, and less of the fluid swelling the authors tie to the nausea.
The mechanism is tidy, which is also the reason to be careful with it. Everything here is preclinical. The work was done in two rodent species and in cell culture, with no human data, and motion sickness in a spun guinea pig is a proxy for the human experience, not the thing itself. Aldosterone and natriuretic peptides sit at the center of blood-pressure and fluid control across the whole body, so a drug that nudged them to settle the inner ear would have to clear a wide margin of cardiovascular and kidney effects before anyone tried it for travel nausea.
Even so, the finding reframes a common complaint as a fluid-balance problem with named parts. Current motion-sickness drugs such as scopolamine and the older antihistamines act on the brain's nausea and balance circuits, and they carry drowsiness and dry-mouth costs that keep people from using them. A hormone axis inside the inner ear, if it survives past rodents, is a different kind of target, and one where the body already makes both the trigger and the brake.